Baby food maker Mead Johnson has upped its full-year earnings forecast after international growth led to a “strong” second quarter for the company.


Mead Johnson said yesterday (23 July) that it now sees earnings per share of US$2.07-2.17 for 2009.


The company, which listed in the US in February, said that when earnings per share is adjusted for costs linked to the IPO, its non-GAAP forecast stands at US$2.15-2.25.


The increase in the non-GAAP forecast is linked to factors including expected sales growth of 5-6% and higher margins.


During the second quarter of 2009, Mead Johnson enjoyed “double-digit” sales growth in Asia, although group turnover fell from US$728.6m a year earlier to US$719.3m due in part to foreign exchange. Net earnings rose from US$114.2m to US$134.5m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

““We continue to see the success of our global growth strategies as evidenced by our strong results for the second quarter,” said CEO Stephen Golsby.


“Our sales performance in constant dollars reflects continued double-digit growth in Asia, as well as strong contributions from our other international operations.”


US pharmaceutical group Bristol-Myers Squibb still owns an 85% stake in Mead Johnson.